Found: 64
Select item for more details and to access through your institution.
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 156, doi. 10.1111/bjh.15405
- By:
- Publication type:
- Article
Bone marrow necrosis as a terminal complication of a very long-lasting polycythemia vera.
- Published in:
- 2007
- By:
- Publication type:
- Case Study
Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2005, v. 6, n. 3, p. 251
- By:
- Publication type:
- Article
Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with Indolent Behavior.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Regulatory T-Cells in Chronic Lymphocytic Leukemia and Autoimmune Diseases.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2012, v. 4, n. 1, p. 1, doi. 10.4084/MJHID.2012.053
- By:
- Publication type:
- Article
Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 103, doi. 10.1111/bjh.18129
- By:
- Publication type:
- Article
Venetoclax in CLL patients who progress after B‐cell Receptor inhibitor treatment: a retrospective multi‐centre Italian experience.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 1, p. e8, doi. 10.1111/bjh.16123
- By:
- Publication type:
- Article
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 1, p. 156, doi. 10.1111/bjh.15405
- By:
- Publication type:
- Article
NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 4, p. 597, doi. 10.1111/bjh.14843
- By:
- Publication type:
- Article
Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. E24, doi. 10.1002/ajh.26779
- By:
- Publication type:
- Article
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. E176, doi. 10.1002/ajh.26502
- By:
- Publication type:
- Article
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E306, doi. 10.1002/ajh.26235
- By:
- Publication type:
- Article
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E269, doi. 10.1002/ajh.26201
- By:
- Publication type:
- Article
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. E168, doi. 10.1002/ajh.26127
- By:
- Publication type:
- Article
Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ET<sub>A</sub> Receptor.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0098818
- By:
- Publication type:
- Article
Extensive toxic epidermal necrolysis following brentuximab vedotin administration.
- Published in:
- 2015
- By:
- Publication type:
- Letter
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.
- Published in:
- 2014
- By:
- Publication type:
- Letter
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 9, p. 1509, doi. 10.1007/s00277-014-2080-6
- By:
- Publication type:
- Article
Vitamin D and non-Hodgkin lymphomas, trends from an Italian monocentric study.
- Published in:
- Panminerva Medica, 2021, v. 63, n. 4, p. 547, doi. 10.23736/S0031-0808.21.04501-8
- By:
- Publication type:
- Article
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3240, doi. 10.3390/cancers13133240
- By:
- Publication type:
- Article
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 4, p. 493, doi. 10.1111/ejh.13573
- By:
- Publication type:
- Article
Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors.
- Published in:
- Cancer (0008543X), 1996, v. 77, n. 12, p. 2476, doi. 10.1002/(SICI)1097-0142(19960615)77:12<2476::AID-CNCR10>3.0.CO;2-P
- By:
- Publication type:
- Article
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221127550
- By:
- Publication type:
- Article
Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
- Published in:
- European Journal of Haematology, 2010, v. 85, n. 6, p. 502, doi. 10.1111/j.1600-0609.2010.01527.x
- By:
- Publication type:
- Article
Evaluation of the prognostic relevance ofl-selectin and ICAM1 expression in myelodysplastic syndromes.
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 2, p. 107, doi. 10.1111/j.1600-0609.2007.00986.x
- By:
- Publication type:
- Article
Consolidation and Maintenance Immunotherapy With Rituximab Improve Clinical Outcome in Patients With B-cell Chronic Lymphocytic Leukemia.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 1, p. 119, doi. 10.1002/cncr.23144
- By:
- Publication type:
- Article
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP‐70‐negative chronic lymphocytic leukemiaPresented in part at the 46th Annual Meeting of the American Society of Hematology, San Diego, California, December 4–7, 2004.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 12, p. 2743, doi. 10.1002/cncr.21535
- By:
- Publication type:
- Article
Increased levels of circulating interleukin-6 in patients with newly diagnosed non-Hodgkin's lymphomas.
- Published in:
- American Journal of Hematology, 1994, v. 46, n. 2, p. 160, doi. 10.1002/ajh.2830460227
- By:
- Publication type:
- Article
Regulation of HIF-1 α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S214, doi. 10.1016/j.clml.2018.07.076
- By:
- Publication type:
- Article
Opioids in pain management of blood-related malignancies.
- Published in:
- Annals of Hematology, 2006, v. 85, n. 8, p. 489, doi. 10.1007/s00277-005-0062-4
- By:
- Publication type:
- Article
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.
- Published in:
- Journal of Translational Medicine, 2010, v. 8, p. 23, doi. 10.1186/1479-5876-8-23
- By:
- Publication type:
- Article
Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.
- Published in:
- Journal of Translational Medicine, 2006, v. 4, p. 11, doi. 10.1186/1479-5876-4-11
- By:
- Publication type:
- Article
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
- Published in:
- Journal of Cellular Physiology, 2006, v. 207, n. 2, p. 354, doi. 10.1002/jcp.20570
- By:
- Publication type:
- Article
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling.
- Published in:
- Journal of Cellular Physiology, 2005, v. 204, n. 1, p. 113, doi. 10.1002/jcp.20269
- By:
- Publication type:
- Article
COVID‐19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 559, doi. 10.1002/hon.3121
- By:
- Publication type:
- Article
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 571, doi. 10.1002/hon.2989
- By:
- Publication type:
- Article
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 712, doi. 10.1002/hon.2916
- By:
- Publication type:
- Article
Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.
- Published in:
- Hematological Oncology, 2013, v. 31, n. 2, p. 348, doi. 10.1002/hon.2028
- By:
- Publication type:
- Article
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.
- Published in:
- Hematological Oncology, 2011, v. 29, n. 2, p. 91, doi. 10.1002/hon.959
- By:
- Publication type:
- Article
How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia.
- Published in:
- Hematological Oncology, 2009, v. 27, n. 4, p. 186, doi. 10.1002/hon.900
- By:
- Publication type:
- Article
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 6, p. 529, doi. 10.1002/ajh.24714
- By:
- Publication type:
- Article
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 6, p. 628, doi. 10.1002/ajh.23170
- By:
- Publication type:
- Article
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 12, p. 1007, doi. 10.1002/ajh.22171
- By:
- Publication type:
- Article
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
- Published in:
- Journal of Hematology & Oncology, 2013, v. 6, n. 1, p. 3, doi. 10.1186/1756-8722-6-83
- By:
- Publication type:
- Article
ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 4, p. 596, doi. 10.1111/bjh.12258
- By:
- Publication type:
- Article
Clinical significance of c.7544-7545 del CT NOTCH1 mutation in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 3, p. 415, doi. 10.1111/bjh.12128
- By:
- Publication type:
- Article
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 1, p. 3, doi. 10.1111/j.1365-2141.2010.08440.x
- By:
- Publication type:
- Article
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53<sup>wild-type</sup> CLL with a poor cytotoxic response to Nutlin-3.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38<sup>+</sup>CD49d<sup>+</sup> chronic lymphocytic leukaemia cells.
- Published in:
- 2010
- By:
- Publication type:
- Letter
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2010, v. 149, n. 3, p. 383, doi. 10.1111/j.1365-2141.2010.08098.x
- By:
- Publication type:
- Article